论文部分内容阅读
杜邦制药公司同意将它的专利技术Cre-lox的许可证授予Glaxo Wellcome公司,它声称,Cre-lox技术相当于一把破译基因功能的分子剪刀,从而了解人体的疾病。杜邦公司把Cre-lox技术描述成是利用Cre重组酶和lox DNA位置将DNA重新固定在特定位置上,它称该技术在基础医学研究中的有效性得到了普遍认可。Cre-lox定位重组技术在培养转基因老鼠试验中显示了强大的效力,在此试验中特定基因借助该技术能在特定时间内从
DuPont Pharmaceuticals agreed to grant Glaxo Wellcome a license for its patented Cre-lox technology. It claims that Cre-lox technology is equivalent to a molecular scissors that deciphers genetic functions to understand human diseases. DuPont described the Cre-lox technology as using Cre recombinase and lox DNA sites to relocate DNA to a specific location. It claims that the technology has gained general acceptance in basic medical research. Cre-lox localization and recombination technology has shown strong efficacy in the cultivation of transgenic mice. In this experiment, specific genes can use this technology to